BRAF mutations and MEK inhibitors
Channel: Target Cancer
Date: 2022-08-31

Can standard treatments for melanoma treat brain cancer? New targeted therapies are available, but we need a system to better identify the best treatments for a particular patient. 

Watch the full interview with Dr. Santosh Kesari and Dr. Sanjay Juneja:
https://www.youtube.com/watch?v=Jwxsbkg5Wi0

Get access to brain cancer treatment options:
https://www.xcures.com/details/brain

#braincancer #melanoma #braintumor #glioma #BRAF

🔔 Like, Subscribe, and Share to see more of this type of content!

— ABOUT DR SANTOSH KESARI —

Dr. Santosh Kesari is a board-certified neurologist and neuro-oncologist and is currently the Chair and Professor at the Department of Translational Neurosciences and Neurotherapeutics, Saint John’s Cancer Institute. He is also the Director of Neuro-oncology at Pacific Neuroscience Institute, Providence Saint John’s Health Center and Providence Little Company of Mary Medical Center Torrance, and leads the Pacific Neuroscience Research Center at Pacific Neuroscience Institute. Furthermore, Dr. Santosh is on the advisory board of the American Brain Tumor Association, San Diego Brain Tumor Foundation, Chris Elliott Fund, Nicolas Conor Institute, Voices Against Brain Cancer, and Philippine Brain Tumor Alliance.

Dr. Kesari is ranked among the top 1% of neuro-oncologists and neurologists in the nation and is a winner of an Innovation Award by the San Diego Business Journal. He has been the author of over 250 scientific publications, reviews, or books and is also the inventor on several patents.

— ABOUT DR SANJAY JUNEJA — 

Dr. Sanjay Juneja is a triple board-certified Hematologist & Medical Oncologist serving as Chief of Oncology Service at Baton Rouge General Hospital, a social & news media personality known as the 'TheOncDoc' with over half a million followers, and one of fifteen social media doctors participating in the Healthcare Leaders in Social Media Round Table Series for the White House. 

He has been featured by The Washington Post as well as dozens of national podcasts and regional news channels (PBS, CBS, NBC, NPR), and has given keynote speeches and partnered with the American Cancer Society, BeTheMatch, Leukemia & Lymphoma Society, Harvard University, Louisiana Department of Health and several others. 

— ABOUT xCURES — 

The xCures platform is a direct-to-patient and direct-to-physician portal that identifies the most promising treatment options for advanced cancer patients who are not responding to standard of care therapies.

The platform captures data that also helps accelerate the development of promising new cancer drugs, expand the approved uses of existing drugs, and demonstrate value for reimbursement.

Learn more at: https://xcures.com/
Facebook: https://www.facebook.com/xcures.platform/
TikTok: https://www.tiktok.com/@xcures.platform
Instagram: https://www.instagram.com/xcures.platform/
LinkedIn: https://www.linkedin.com/company/xcures/
Twitter: https://twitter.com/xcures_platform

TARGET: Cancer Podcast
Homepage: https://xcures.com/target-cancer-podcast/
YouTube: https://www.youtube.com/TargetCancer
Spotify: https://open.spotify.com/show/2xMG5y5gOoIut5Ykvm63XO?si=0b478259417f40f4
iTunes: https://podcasts.apple.com/us/podcast/target-cancer-podcast/id1593087681